secwatch.observer — SEC 8-K summary
======================================

Issuer:     Celldex Therapeutics, Inc. (CLDX)
CIK:        0000744218
Form:       8-K
Filed at:   2025-06-06T23:59:59+00:00
Accession:  0001104659-25-057066
Event type: leadership
Sentiment:  neutral
Materiality: 0.50
Item codes: 5.02, 5.07, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Celldex shareholders approve equity plan increase, elect directors including Denice Torres
--------------------------------------------------------------------------------

- Stockholders approved 2M share increase to 2021 Omnibus Plan (total 9.5M shares) with 53.2M for, 963K against.
- All 9 director nominees elected, including new director Denice Torres; Karen Shoos' term ended.
- Ratification of PricewaterhouseCoopers as auditor for FY2025: 58M for, 119K against.
- Advisory say-on-pay approved: 53.5M for, 627K against.
- Harry Penner elected Chair of board post-meeting.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/744218/000110465925057066/0001104659-25-057066-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/744218/000110465925057066/tm2517205d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-057066

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer